Showing results (1391-1400 of 5,496) with videos related to
Sort By:
Pageof 550
Proceedings of the National Academy of Sciences of the United States of America|September 1, 1987
Integration host factor is required for the DNA inversion that controls phase variation in Escherichia coliB I Eisenstein, D S Sweet, V Vaughn, et al.Pediatric Nephrology (Berlin, Germany)|July 1, 1989
Zinc and copper balance in children on continuous ambulatory peritoneal dialysisT Tamura, W H Vaughn, F B Waldo, et al.Journal of Educational Psychology|August 23, 2019
Examining Sources and Mechanisms of Reading Comprehension Difficulties: Comparing English Learners and Non-English Learners within the Simple View of ReadingEunsoo Cho, Philip Capin, Greg Roberts, et al.Journal of Women'S Health (2002)|July 18, 2019
A Randomized Clinical Trial Comparing the Impact of a Web-Based Multimedia Intervention Versus an Educational Pamphlet on Patient Outcomes in Breast Cancer Survivors with Chronic Secondary LymphedemaSheila H Ridner, Mary S Dietrich, Amanda J Davis, et al.Annals of Global Health|February 20, 2019
Peace in Guatemala and Immigrant Health in the United StatesJeremy C Green, Eric Adjei Boakye, Amanda Schoening, et al.Scientific Reports|March 7, 2019
Water-Deprived Parasitic Wasps (Pachycrepoideus vindemmiae) Kill More Pupae of a Pest (Drosophila suzukii) as a Water-Intake StrategyCherre Sade Bezerra Da Silva, Briana Elizabeth Price, Vaughn M WaltonAnticancer Research|March 16, 2004
HIF transcription factor expression and induction of hypoxic response genes in a retroperitoneal angiosarcomaW Kimryn Rathmell, Geza Acs, M Celeste Simon, et al.Journal of Chemical Ecology|April 13, 2004
Defense tradeoffs in fleshy fruits: effects of resource variation on growth, reproduction, and fruit secondary chemistry in Solanum carolinenseMartin L Cipollini, Eric Paulk, Kim Mink, et al.Journal of Chemical Ecology|April 21, 2005
Biofumigant compounds released by field pennycress (Thlaspi arvense) seedmealSteven F Vaughn, Terry A Isbell, David Weisleder, et al.American Journal of Clinical Oncology|February 8, 2013
Phase II clinical trial of oxaliplatin and bevacizumab in refractory germ cell tumorsAmit Jain, Mary J Brames, David J Vaughn, et al.Pageof 550